FIELD: medicine.
SUBSTANCE: conjugated capsular saccharides of serogroups B, C, W135 and Y N.meningitidis are safe and immunogenic when combined in a single dose. This effect is retained when a conjugated capsular saccharide of serogroup A is added. Given conjugated antigens can be stably combined in a single aqueous dose without lyophilisation required. A wide spectrum of protection against serogroup B infection can be assured by additional application of certain polypeptide antigens - protein NadA in the oligomeric form, proteins '741', '936' ,'953', '287' which can be combined with saccharide Neisseria antigens without loosing protective efficiency of any of five serogroups. Efficiency of the vaccine remains, e.g. when Hib-conjugate added. Efficiency of a conjugate of serogroup W135 increases when proteantigens derived from Neisseria stain of serogoup D added. When Hib-conjugate added to meningococcal conjugate, total activity against serogroup W135 increases. The aqueous immunogenic meningococcal compositions (versions) derived from the capsular antigens are intended for immunisation against bacterial meningitis, inducing a specific immune response in a mammal. When antigen Hib and antigen Str. pneumoniae are used as a part of the composition, preventive protection of a mammal against the disease caused H.influenzae type B and Str. pneumoniae is provided.
EFFECT: produced aqueous vaccine compositions provide a wide spectrum of immunologic protection against meningococcal infection of serogroup B.
19 cl
